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Abstract 
Introduction: There is a paucity of predictive biomarkers of efficacy for tyrosine kinase inhibitors (TKIs), 
which are cornerstone therapies for solid tumors. Previous studies identified a positive association between 
treatment-emergent macrocytosis and both progression-free survival (PFS) and overall survival (OS) in 
sunitinib-treated patients. We aimed to investigate similar associations in additional TKIs used for the 
treatment of solid tumors.  
 
Methods: This was a single-institution retrospective study that included patients if they were ≥18 years with 
solid tumor diagnoses (e.g., gastrointestinal stromal tumor, hepatocellular carcinoma, renal cell carcinoma 
[RCC], and thyroid cancer), and who were treated with axitinib, cabozantinib, imatinib, pazopanib, 
sorafenib, or sunitinib between 1/1/2010 and 8/15/2017. Patients were excluded if they lacked a baseline 
and at least one on-treatment mean corpuscular volume (MCV) measurement, or if treatment was in the 
neoadjuvant/adjuvant setting. Univariate survival analyses were performed using a log-rank test, while Cox 
Proportional Hazards were used for multivariable survival analyses. 
 
Results: In multivariable analyses of the entire study cohort (n=209), which accounted for the effects of 
solid tumor diagnosis and TKI selection, on-treatment MCV ≥100 fL and ΔMCV ≥10 fL from baseline 
were significantly associated with increased OS (P=0.013 and P=0.038, respectively) and PFS (P=0.005 
and P=0.011, respectively). In multivariable analyses of the RCC subgroup (n=107), on-treatment MCV 
≥100 fL and ΔMCV ≥10 fL from baseline were significantly associated with increased OS (P=0.034 and 
P=0.038, respectively) and PFS (P=0.0001 and P=0.026). In multivariable analyses of pazopanib-treated 
patients (n=80), only on-treatment MCV ≥100 fL was associated with increased PFS (P=0.018). 
 
Conclusions: Treatment-emergent macrocytosis predicts TKI treatment efficacy in solid tumors, 
particularly in RCC and pazopanib-treated patients. These study results provide compelling rationale to 
pursue future lines of prospective research inquiry clinically to validate these data, and translationally to 
better understand the molecular mechanisms underlying associations between treatment-emergent 
macrocytosis and survival.  
Introduction 
Cancer remains a public health challenge for a significant proportion of the United States (U.S.) 
population. In 2019 alone, it is estimated that almost 1.6 million patients were diagnosed with a solid organ 
malignancy in the U.S.1 While treatment paradigms for these diseases have evolved, metastatic disease 
remains incurable. The five-year survival rates for metastatic gastrointestinal stromal tumor (GIST) and 
metastatic thyroid cancer are 78% and 52%, respectively, but only 12% for metastatic renal cell carcinoma 
(RCC) and 2% for metastatic hepatocellular carcinoma (HCC).2–4 These statistics highlight that 1) there is 
a disparity in the natural course of solid organ cancer progression and pathogenicity, but also that 2) there 
is still an unmet need for further treatment optimization across solid tumor types.  
Over the past two decades, orally administered tyrosine kinase inhibitors (TKIs) have become 
cornerstone therapies in many hematologic and solid tumor types, and their use in the setting of advanced 
and metastatic disease have been adopted into seminal guidelines.5 TKIs have been designed to effectively 
inhibit receptor tyrosine kinases (RTKs), and abrogate reactions that initiate signal transduction cascades 
responsible for various cellular responses such as angiogenesis, proliferation and differentiation.6,7 TKIs 
derive their efficacy from their potency against specific RTKs, but a major consequence of potent RTK 
activity are TKI-induced adverse events (AEs) that can result in dose reductions, and even treatment 
interruptions or discontinuations.8–10 A significant proportion of precision medicine initiatives in oncology 
over the past three decades have focused primarily on somatic and genomic mutations as predictive 
biomarkers, however, pharmacodynamic biomarkers of drug effects can help identify patient subgroups that 
will best respond to TKI treatments. Historically, TKI-induced AEs, such has hand-foot skin reaction and 
hypertension, have been evaluated as potential pharmacodynamic biomarkers of treatment effectiveness.11–
17 Unfortunately, a major issue for clinicians who treat patients with solid malignancies is the paucity of 
validated predictive pharmacodynamic biomarkers that have been successfully incorporated into routine 
clinical practice.18,19 
Macrocytosis is typified by an increased red blood cell size, and is defined as a mean corpuscular volume 
(MCV) >100 femtoliters (fL).20 Macrocytosis with megaloblastic anemia is caused by a vitamin B12 and 
folic acid deficiency secondary to co-morbidities that include atrophic gastritis, enteral malabsorption, 
primary bone marrow disorders, or pharmacotherapy (e.g., anticonvulsants or treatments for human 
immunodeficiency virus), and results in dysplastic hematopoiesis.20–22 In contrast, macrocytosis without 
megaloblastic anemia can be caused by alcohol abuse, hypothyroidism, myelodysplasia, hemolysis, 
hemorrhage, or splenectomy.20–22 TKI treatment has also been implicated as a cause of macrocytosis, and 
several previous reports have described cases of TKI-induced macrocytosis where patients treated with 
sunitinib or imatinib have experienced MCVs >100 fL.23–27 More recently, three studies described a 
significant association between sunitinib-induced macrocytosis and increased progression-free survival 
(PFS).22,28,29  
The primary goal of this study was to evaluate treatment-induced macrocytosis as a clinically important 
predictive biomarker of survival (PFS and overall survival [OS]). To evaluate this gap in knowledge, data 
were collected from patients treated for solid tumor diagnoses with axitinib, cabozantinib, imatinib, 
pazopanib, sorafenib, and sunitinib at the University of North Carolina Medical Center (UNCMC). Then, 
associations between treatment-emergent MCV ≥100 fL and both PFS and OS, as well as associations 
between a change in MCV by ≥10 fL (ΔMCV ≥10 fL) from baseline and both PFS and OS, were evaluated.  
 
Patients and Methods 
This was a single-institution retrospective study of UNCMC patients with a solid malignancy diagnosis 
who were treated with at least one TKI between January 2010 and August 2017 (UNC IRB 17-2003). 
Patients were eligible for inclusion if they were at least 18 years-old, had a solid tumor diagnosis, and were 
treated with at least one of the following TKIs for at least one month: axitinib, cabozantinib, imatinib, 
pazopanib, sorafenib, or sunitinib. Patients were excluded from eligibility if they were pregnant during 
treatment, or if patients received neoadjuvant or adjuvant TKI treatment.  
The Carolina Data Warehouse for Health (CDW-H), which is a central data repository containing 
clinical, research, and administrative data sourced from the UNC Health Care System, was queried to 
identify patients who could be eligible for this study. Data was manually extracted from the UNCMC 
electronic medical record (Epic@UNC) for those patients meeting the inclusion criteria. Data extracted 
from Epic@UNC included: patient baseline clinical and demographic information, TKI treatment details, 
laboratory values for the first year of treatment, and information related to survival (i.e., PFS and OS). 
Hematological parameters such as hemoglobin (Hgb), MCV and red cell distribution width (RDW) were 
collected at baseline and during treatment with TKIs. In addition to baseline, Hgb, MCV and RDW levels 
were collected at 1, 3, 6, 9 and 12 months of treatment, or until treatment TKI discontinuation date (if it 
occurred within a year of treatment start date). For those patients, macrocytosis was defined as an on-
treatment MCV >100 fL at any point during treatment.20,21,30 We also collected information about patients 
that experienced a ΔMCV ≥10 fL from baseline while on TKI treatment for exploratory analyses. Patients 
prescribed a subsequent TKI were included as distinct observations if there was at least a one week wash-
out period, and if new baseline measurements were collected. PFS was defined as the time from the date of 
treatment start until the date of evidence of progressive disease or death. OS was defined as the time from 
date of treatment start until the date of death from any cause. PFS and OS were censored if PFS or OS had 
not been reached, or at the last known contact date if patient was lost to follow-up. Additionally, PFS was 
censored at date of drug discontinuation for reasons other than progression (e.g., discontinuation due to 
treatment-induced toxicities).  
 
Statistical Analyses 
Descriptive statistics were used to characterize the patient population and categorical variables were 
summarized as counts and percentages. Continuous variables were summarized as medians (with 
interquartile range [IQR]), or as means (with standard deviation), as appropriate. All inferential statistical 
testing were two-sided with an a priori alpha level set to 0.05 (P<0.05). Differences between baseline 
clinical and demographic factors were evaluated in patients who experienced treatment-emergent MCV 
>100 fL versus those who did not. Analyses of paired categorical variables used McNemar’s test or Fisher’s 
exact test where appropriate, while analyses of continuous variables used a paired t-test or Mann-Whitney 
U test where appropriate. Time to event survival analyses (the effect of treatment-emergent MCV >100 fL 
and ΔMCV ≥10 fL from baseline) were estimated by a log-rank test using Kaplan-Meier curves. Time-
dependent Cox Proportional Hazard models were used to estimate multivariable time-to-event survival 
analyses. Additionally, Cox Proportional Hazard models were used to derive hazard ratios (HR) and 95% 
confidence intervals (CI). Forward selection (P<0.1) and backward elimination (P<0.05) were used to 
identify important covariates to be included in final multivariable models. All statistical analyses were 
performed using SAS JMP Pro 14.0.0 (SAS Institute, Cary, NC, USA), and Kaplan Meier plots were 
generated using GraphPad Prism version 8.2 (GraphPad Software, San Diego, CA).  
 
Results 
Study population and baseline characteristics 
A total of 209 patients treated with orally administered TKIs were included in the study (Figure 1). The 
most common diagnoses were RCC (n=107) and HCC (n=44), while the most commonly prescribed TKI’s 
were pazopanib (n=80) and sorafenib (n=65). The median age at start of TKI was 62, approximately 68% 
of the cohort was male, and the majority of patients included in the study were either White (67%) or Black 
(28%).  
Table 1 provides a comprehensive summary of baseline clinical and demographic information for the 
study cohort, and comparisons between patients with on-treatment MCV ≥100 fL versus patients with MCV 
<100 fL. Significant differences in baseline demographics and clinical features between patients who 
experienced treatment-emergent macrocytosis versus patients who did not included TKI treatment selection 
(P<0.001), solid tumor diagnosis type (<0.001), baseline serum creatinine (P=0.001), baseline MCV 
(P=0.001), baseline Hgb (P=0.016), baseline alkaline phosphatase (P=0.036), and baseline RDW 
(P=0.046). Only TKI treatment selection and solid tumor diagnosis type remained significant after 
backward elimination (P<0.05), and were included as covariates in final multivariable analyses.  
 
Laboratory changes over time 
Mean time to macrocytosis was 118 days (or approximately 3.9months) for patients who experienced 
MCV >100 fL. Significant treatment-emergent mean MCV increases were observed for cabozantinib 
(ΔMCV by 5.5 fL; P=0.003), imatinib (ΔMCV by 3.7 fL; P=0.002), pazopanib (ΔMCV by 4.5 fL; 
P<0.001), and sunitinib (ΔMCV by 5.6 fL; P<0.001), but significantly decreased for sorafenib (ΔMCV by 
-1.2 fL; P=0.001). At 6 months (the closest time point where MCV was measured near maximum mean 
ΔMCV), MCV had increased by 13.1%, 12.3%, 8.4% and 14.2% in patients treated with cabozantinib, 
imatinib, pazopanib and sunitinib, respectively. Significantly higher treatment-emergent macrocytosis 
prevalence was also observed for pazopanib (P<0.001), and sunitinib (P=0.024). Treatment-emergent RDW 
increases were observed for cabozantinib (ΔRDW by 1.7%; P=0.019), pazopanib (ΔRDW by 1.3%; 
P<0.001), sorafenib (ΔRDW by 0.9%; P<0.001), and sunitinib (ΔRDW by 1.4%; P=0.004) (Table 2). In 
addition, for cabozantinib, pazopanib, sunitinib, and to a lesser extent imatinib, mean MCV began to rise 
after the first month of TKI treatment, and peaked at 6 months of treatment. This is contrasted by sorafenib 
where mean MCV changes began to precipitously decline at 3 months of TKI treatment and continued to 
drop for the entire first 12 months of treatment (Figure 2A). Again, for cabozantinib, pazopanib, sunitinib, 
mean RDW began to increase at the start of TKI treatment, peaked at 3 months, and declined between 3 
and 6 month of treatment before leveling off for the remainder of the first 12 months of treatment (Figure 
2B). Significant treatment-emergent Hgb increases were observed for axitinib (ΔHgb by 2.1 g/dL; 




TKI-induced macrocytosis and survival 
Among the entire study cohort (n=209), median OS was 818 days (IQR 289–1355 days), and both 
treatment-emergent MCV ≥100 fL and ΔMCV ≥10 fL from baseline were significantly associated with OS. 
Patients who experienced a treatment-emergent MCV ≥100 fL (n=40) achieved a median OS of 1339 days 
versus 756 days for patients with MCV <100 fL (n=169) (HR=1.74, 95% CI 1.17–2.59; P=0.018). 
Additionally, patients with a ΔMCV ≥10 fL from baseline (n=52) achieved a median OS of 971 days versus 
646 days for patients with ΔMCV <10 fL from baseline (n=157) (HR=1.64, 95% CI 1.14–2.37; P=0.015). 
When adjusting for the effects of both TKI selection and diagnosis type, the associations between treatment-
emergent MCV ≥100 fL (HR=1.81, 95% CI 1.10–3.10; P=0.013) and ΔMCV ≥10 fL from baseline 
(HR=1.62, 95% CI 1.03–2.59; P=0.038) remained significant (Table 3 and Figure 3).  
Among the entire study cohort, median PFS was 393 days (IQR 155–891 days), but neither treatment-
emergent MCV ≥100 fL nor ΔMCV ≥10 fL from baseline were significantly associated with increased PFS 
(P=0.064 and P=0.130, respectively). However, when adjusting for the effects of TKI selection and 
diagnosis as covariates in multivariable models, patients who experienced a treatment-emergent MCV ≥100 
fL achieved a significantly longer PFS than patients with MCV <100 fL (median PFS 737 vs 365 days; 
HR=2.39, 95% CI 1.43–4.11; P=0.005). In addition, patients who experienced a ΔMCV ≥10 fL from 
baseline also achieved longer PFS than patients versus patients with a ΔMCV <10 fL from baseline (median 
PFS 455 vs 365 days; HR=1.88, 95% CI 1.15–3.07; P=0.011) (Table 3 and Figure 3). 
 
TKI-induced macrocytosis and survival in renal cell carcinoma 
In total, 107 RCC patients were included in the study (n=70 treated with pazopanib, n=18 treated with 
sunitinib, n=11 treated with cabozantinib, and n=8 treated with axitinib). Among these patients, median OS 
was 893 days (IQR 353–1430 days), and both treatment-emergent MCV ≥100 fL and ΔMCV ≥10 fL from 
baseline were significantly associated with OS. RCC patients who experienced a treatment-emergent MCV 
≥100 fL (n=28) achieved a median OS of 1339 days versus a median of 756 days for patients with MCV 
<100 fL (n=79) (HR=1.77, 95% CI 1.08–2.92; P=0.040). Additionally, RCC patients with a ΔMCV ≥10 fL 
from baseline (n=43) achieved a median OS of 1355 days versus 768 days for patients with ΔMCV <10 fL 
from baseline (n=64) (HR=1.71, 95% CI 1.06–2.77; P=0.030). When adjusting for the effects of TKI 
selection, the associations between treatment-emergent MCV ≥100 fL (HR=1.81, 95% CI 1.10–3.10; 
P=0.013) and ΔMCV ≥10 fL from baseline (HR=1.62, 95% CI 1.03–2.59; P=0.038) remained significant 
(Table 3 and Figure 4). 
Among RCC patients, median PFS was 382 days (IQR 163–902 days), and both treatment-emergent 
MCV ≥100 fL and ΔMCV ≥10 fL from baseline were significantly associated with PFS. RCC patients who 
experienced a treatment-emergent MCV ≥100 fL achieved a median PFS of 882 days versus 316 days for 
patients with MCV <100 fL (HR=2.54, 95% CI 1.54–4.20; P=0.0003). Additionally, patients with a ΔMCV 
≥10 fL from baseline achieved a median PFS of 439 days versus a median of 345 days for patients with 
ΔMCV <10 fL from baseline (HR=1.70, 95% CI 1.05–2.89; P=0.031). Moreover, when adjusting for the 
effects of TKI selection, the associations between treatment-emergent MCV ≥100 fL (HR=2.39, 95% CI 
1.43–4.11; P=0.0001) and ΔMCV ≥10 fL from baseline (HR=1.92, 95% CI 1.08–3.36; P=0.026) remained 
significant (Table 3 and Figure 4). 
 
Pazopanib-induced macrocytosis and survival 
In total, 80 patients were treated with pazopanib (n=70 RCC; n=7 sarcoma; n=2 paraganglioma; n=1 
hemangiopericytoma). Among the pazopanib-treated patients, median OS was 902 days (IQR 289–1470 
days), while median PFS was 334 days (IQR 163–789 days). For patients treated with pazopanib, treatment-
emergent MCV ≥100 fL and ΔMCV ≥ 10 from baseline were both associated with improved PFS, but not 
OS. Pazopanib-treated patients who experienced a treatment-emergent MCV ≥100 fL achieved a median 
PFS of 575 days (n=23) versus 273 days for patients with MCV <100 fL (n=57) (HR=1.95, 95% CI 1.10–
3.45; P=0.021). Additionally, patients with a ΔMCV ≥10 fL from baseline achieved a median PFS of 439 
days (n=31) versus 211 days for patients with ΔMCV <10 fL from baseline (n=49) (HR=1.86, 95% CI 
1.01–3.44; P=0.024). When adjusting for the effects of diagnosis type, only the association between 
treatment-emergent MCV ≥100 fL and PFS remained significant (HR=2.11, 95% CI 1.13–4.15; P=0.018) 
(Table 3 and Figure 5). Moreover, among the RCC patients treated with pazopanib, patients who achieved 
a treatment-emergent MCV ≥100 fL (n=20) achieved a significantly longer median PFS than patients with 





















Tables and Figures 
Table 1. Patient Characteristics. Baseline clinical and demographic characteristics are included for 209 
patients included in the final analyses. On-treatment changes in Hgb, MCV, RBC, and RDW are also 
included. Interpatient clinical and demographic characteristics were evaluated between patients who 
developed TKI-induced macrocytosis (treatment-emergent MCV ≥100 fL) versus those who did not, and 
significant results (P<0.05) are bolded below. Abbreviations: Alk Phos, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; CrCl, creatinine clearance; GIST, gastrointestinal 
stromal tumor; HCC, hepatocellular carcinoma; Hgb, hemoglobin; MCV, mean corpuscular volume; RBC, 
red blood cell count; RCC, renal cell carcinoma; RDW, red blood cell distribution width; SCr, serum 
creatinine; Tbili, total bilirubin; TKI, tyrosine kinase inhibitor. 
Variable Whole Cohort (n=209) 
MCV ≥100 fL 
(n= 40) 
MCV <100 fL 
 (n=169) P-Value 
Age, median years (range) 62 (20– 86) 62 (21– 82) 63 (20– 86) 0.535 
Sex, n (%) 
Male 142 (67.9) 32 (80.0) 109 (64.5) 0.063 
Female 67 (32.1) 8 (20.0) 60 (35.5)  
Race/Ethnicity, n (%) 
White 140 (67.0) 31 (77.5) 109 (64.5) 0.137 
Black 58 (27.8) 9 (22.5) 49 (29.0) 0.556 
Hispanic 4 (1.9) 0 (0) 4 (2.4) N/A 
Native American 4 (1.9) 0 (0) 4 (2.4) N/A 
Asian 2 (1) 0 (0) 2 (1.2) N/A 
Other 1 (< 1) 0 (0) 1 (< 1) N/A 
Type of TKI, n (%) 
Pazopanib 80 (38.3) 23 (57.5) 57 (33.7) 0.007 
Sorafenib 65 (31.1) 1 (2.5) 64 (37.9) <0.001 
Sunitinib 27 (12.9) 8 (20.0) 19 (11.2) 0.186 
Cabozantinib 18 (8.6) 6 (15.0) 12 (7.1) 0.121 
Imatinib 11 (5.3) 1 (2.5) 10 (5.9) 0.695 
Axitinib 8 (3.8) 1 (2.5) 7 (4.2) 0.999 
Previous Lines of Treatment, n (%) 
0 145 (69.4) 25 (62.5) 120 (71.0) 0.341 
1 38 (18.2) 10 (25.0) 28 (16.6) 0.254 
2+ 26 (12.4) 5 (12.5)) 21 (12.4) 0.999 
Subsequent Lines of Treatment, n (%)  
0 114 (54.5) 19 (47.5) 95 (56.2) 0.378 
1 52 (24.9) 12 (30.0) 40 (23.7) 0.419 
2 29 (13.9) 7 (17.5) 22 (13.0) 0.452 
3+ 14 (6.7) 2 (5.0) 12 (7.1) 0.999 
Diagnosis, n (%) 
RCC 107 (51.2) 28 (70.0) 79 (46.7) 0.003 
HCC 44 (21.1) 1 (2.5) 43 (25.4) <0.001 
Thyroid 24 (11.5) 3 (7.5) 21 (12.4) 0.581 
Other 21 (10.1) 6 (16.0) 15 (9.0) 0.387 
GIST 13 (6.1) 2 (5.0) 11 (6.5) 0.999 
Baseline Laboratory Parameters, median (range) 
Alk Phos (U/L) 105 (42–797) 93 (53–357) 107 (42–797) 0.036 
ALT (U/L) 33 (5–462) 36 (13–232) 32 (5–462) 0.396 
AST (U/L) 30 (7–378) 30 (10–194) 30 (7–378) 0.143 
Tbili (mg/dL) 0.6 (0.1–4.2) 0.6 (0.2–2.1)) 0.6 (0.1–4.2) 0.169 
CrCl (mL/min) 92.5 (7.62–235.7)  84.2 (22.8–160.0) 95.2 (7.6–235.7) 0.077 
SCr (mg/dL) 0.94 (0.34–10.1) 1.15 (0.62–2.24) 0.91 (0.34–10.1) 0.001 
Weight (kg) 81.2 (38.4–212.0) 83.1 (43.1–169.8) 80.4 (38.4–212.0) 0.457 
Baseline Hematologic Parameters, median (range) 
MCV (fL) 89.0 (70.3–116.0) 93.0 (74.0–99.5) 88.0 (70.3–116.0) 0.001 
RBC (1012 cells/L) 4.18 (2.91–6.28) 4.13 (3.11–5.47) 4.19 (2.91–6.28) 0.778 
RDW (%) 15.0 (11.9–26.0) 14.3 (12.1–21.8) 15.1 (11.9–26.0) 0.046 
Hgb (g/dL) 12.4 (7.9–17,9) 13.1 (9.1–16.9) 12.2 (7.9–17.9) 0.016 
 
  
Table 2. Comparison of baseline and on-treatment hematologic parameters among TKIs. Significant 
differences (P<0.05) between baseline and on-treatment characteristics are bolded below Abbreviations: 
Hgb, hemoglobin; MCV, mean corpuscular volume; RBC, red blood cell; RDW, red cell distribution width; 
SD, standard deviation; TKI, tyrosine kinase inhibitor. 
TKI Characteristic Baseline On-Treatment P-value 
Axitinib (n=8) Hgb (g/dL), mean (SD) 12.1 (2.0) 14.2 (1.6) 0.012 
 MCV (fL), mean (SD) 93.9 (4.6) 89.6 (6.3) 0.052 
 MCV >100 fL, n (%) 0 (0.0) 1 (12.5) >0.999 
 RBC (1012/L), mean (SD) 3.91 (0.44) 4.85 (0.51) 0.001 
 RDW (%), mean (SD) 15.9 (1.7) 15.4 (1.4) 0.343 
Cabozantinib (n=18) Hgb (g/dL), mean (SD) 11.7 (1.8) 11.6 (2.6) 0.857 
 MCV (fL), mean (SD) 88.5 (8.5) 94.0 (7.4) 0.003 
 MCV >100 fL, n (%) 1 (5.6) 6 (33.3) 0.088 
 RBC (1012/L), mean (SD) 4.08 (7.2) 3.65 (0.95) 0.125 
 RDW (%), mean (SD) 16.2 (2.5) 17.9 (2.4) 0.019 
Imatinib (n=11) Hgb (g/dL), mean (SD) 11.4 (2.2) 11.8 (1.6) 0.471 
 MCV (fL), mean (SD) 85.1 (5.4) 88.8 (4.4) 0.002 
 MCV >100 fL, n (%) 0 (0.0) 1 (9.1) >0.999 
 RBC (1012/L), mean (SD) 4.13 (0.59) 4.06 (0.44) 0.704 
 RDW (%), mean (SD) 16.1 (3.4) 15.7 (1.6) 0.652 
Pazopanib (n=80) Hgb (g/dL), mean (SD) 12.3 (2.2) 13.4 (2.1) <0.001 
 MCV (fL), mean (SD) 87.1 (7.1) 91.6 (7.3) <0.001 
 MCV >100 fL, n (%) 2 (2.5) 23 (28.8) <0.001 
 RBC (1012/L), mean (SD) 4.30 (0.66) 4.42 (0.59) 0.084 
 RDW (%), mean (SD) 15.4 (2.3) 16.7 (2.0) <0.001 
Sorafenib (n=65) Hgb (g/dL), mean (SD) 12.5 (1.8) 13.1 (1.9) <0.001 
 MCV (fL), mean (SD) 91.7 (7.6) 90.5 (8.1) 0.001 
 MCV >100 fL, n (%) 0 (0.0) 1 (1.5) >0.999 
 RBC (1012/L), mean (SD) 4.19 (0.68) 4.42 (0.70) <0.001 
 RDW (%), mean (SD) 15.0 (1.7) 15.9 (1.9) <0.001 
Sunitinib (n=27) Hgb (g/dL), mean (SD) 11.9 (2.0) 11.9 (1.5) 0.857 
 MCV (fL), mean (SD) 87.4 (8.7) 93.0 (8.5) <0.001 
 MCV >100 fL, n (%) 1 (3.7) 8 (28.0) 0.024 
 RBC (1012/L), mean (SD) 4.16 (0.67) 3.89 (0.55) 0.005 
 RDW (%), mean (SD) 15.8 (2.7) 17.2 (2.2) 0.004 
 
  
Table 3. Overall survival and progression-free survival. OS and PFS results for the whole cohort, as 
well as subgroups with ≥50 patients in each subgroup. These included patients diagnosed with RCC 
(n=107), and patients treated with pazopanib (n=80). Patients with treated with sorafenib (n=65) were not 
evaluated because only one patient experienced MCV ≥100 (1.5%). Multivariable models were adjusted 
for the effects of diagnosis type and TKI treatment selection. Significant observations (P<0.05) are bolded 
below. Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; MCV, 
mean corpuscular volume; ΔMCV, change in MCV; OS, overall survival; PFS, progression-free survival; 




Unadjusted HR, 95% CI;  
P-Value 
Adjusted HR, 95% CI;  
P-Value 
All Patients (n=209) 
OS and on-treatment MCV ≥100 fL 1.74 (1.17–2.59); P=0.018 1.81 (1.10–3.10); P=0.013 
PFS and on-treatment MCV ≥100 fL 1.52 (0.98–2.30); P=0.064 2.39 (1.43–4.11); P=0.005 
OS and ΔMCV ≥10 fL from baseline 1.64 (1.14–2.37); P=0.015 1.62 (1.03–2.59); P=0.038 
PFS and ΔMCV ≥10 fL from baseline 1.35 (0.92–1.98); P=0.130 1.88 (1.15–3.07); P=0.011 
Patients with RCC (n=107) 
OS and on-treatment MCV ≥100 fL 1.77 (1.08–2.92); P=0.040 1.81 (1.05–3.30); P=0.034 
PFS and on-treatment MCV ≥100 fL 2.54 (1.54–4.20); P=0.0003 2.39 (1.43–4.11); P=0.0001 
OS and ΔMCV ≥10 fL from baseline 1.71 (1.06–2.77); P=0.030 1.62 (1.03–2.59); P=0.038 
PFS and ΔMCV ≥10 fL from baseline 1.70 (1.05–2.89); P=0.031 1.92 (1.08–3.36); P=0.026 
Pazopanib-Treated Patients (n=80) 
OS and on-treatment MCV ≥100 fL 1.76 (0.99–3.13); P=0.079 1.78 (0.95–3.56); P=0.071 
PFS and on-treatment MCV ≥100 fL 1.95 (1.10–3.45); P=0.021 2.11 (1.13–4.15); P=0.018 
OS and ΔMCV ≥10 fL from baseline 1.47 (0.85–2.54); P=0.178 1.53 (0.85–2.80); P=0.153 
PFS and ΔMCV ≥10 fL from baseline 1.86 (1.01–3.44); P=0.024 1.69 (0.86–3.26); P=0.123 
Figure 1. Study Schematic. A total of 932 potentially eligible patients were identified. Study medications 
included axitinib, cabozantinib, imatinib, pazopanib, sorafenib, and sunitinib. After multiple rounds of 
screening and evaluation, a total of 209 patients comprised the final cohort of the study. Abbreviations: 
MCV, mean corpuscular volume; TKI, tyrosine kinase inhibitor.  
 
  
Figure 2. Time course of hematologic parameters during TKI treatment. Panel A depicts the course of 
mean MCV levels during the first 12 months of TKI therapy. Panel B depicts the course of mean RDW 
percentage during the first 12 months of TKI therapy. Panel C depicts the course of mean Hgb levels during 
the first 12 months of TKI therapy. Panel D depicts the course of mean RBC cell number (1012/L) during 
the first 12 months of TKI therapy. Abbreviations: Hgb, hemoglobin; MCV, mean corpuscular volume; 




Figure 3. Cumulative Incidence Plots for OS and PFS in Entire Study Cohort (n=209). Panels A-B 
depict differences in OS and PFS, respectively, between patients who experienced on-treatment MCV ≥100 
fL versus those patients with on-treatment MCV <100 fL. Panels C-D depict differences in OS and PFS, 
respectively, between patients who experienced ΔMCV ≥10 fL from baseline versus those patients with 
ΔMCV <10 fL from baseline. Vertical bars on the survival curves indicate censored observations. P-values 
were adjusted for the effects of treatment selection, and solid tumor diagnosis type. Abbreviations: Adj. P, 




Figure 4. Cumulative Incidence Plots for OS and PFS among Patients with RCC (n=107). Panels A-B 
depict differences in OS and PFS, respectively, between patients who experienced on-treatment MCV ≥100 
fL versus those patients with on-treatment MCV <100 fL. Panels C-D depict differences in OS and PFS, 
respectively, between patients who experienced ΔMCV ≥10 fL from baseline versus those patients with 
ΔMCV <10 fL from baseline. Vertical bars on the survival curves indicate censored observations. Vertical 
bars on the survival curves indicate censored observations. P-values were adjusted for the effects of 
treatment selection. Abbreviations: Adj. P, adjusted p-value; MCV, mean corpuscular volume; ΔMCV, 
change in MCV; OS, overall survival; PFS, progression-free survival, RCC, renal cell carcinoma.  
 
  
Figure 5. Cumulative Incidence Plots for OS and PFS among Patients Treated with Pazopanib (n=80). 
Panels A-B depict differences in OS and PFS, respectively, between patients who experienced on-treatment 
MCV ≥100 fL versus those patients with on-treatment MCV <100 fL. Panels C-D depict differences in OS 
and PFS, respectively, between patients who experienced ΔMCV ≥10 fL from baseline versus those patients 
with ΔMCV <10 fL from baseline. Vertical bars on the survival curves indicate censored observations. 
Vertical bars on the survival curves indicate censored observations. P-values were adjusted for solid tumor 
diagnosis type. Abbreviations: Adj. P, adjusted p-value; MCV, mean corpuscular volume; ΔMCV, change 






Currently, a paucity of validated pharmacodynamic biomarkers that have been successfully 
incorporated into routine clinical practice limits prediction of which patients will most benefit from TKI 
treatment.18,19,31 Results from this study, however, provide initial evidence that treatment-emergent 
macrocytosis could be used a predictive biomarker of TKI response in patients with solid tumors. This study 
revealed, for the first time, that pazopanib-induced macrocytosis was associated with increased PFS. 
Second, this study, for the first time, detected an association between treatment-emergent macrocytosis and 
OS in a patient population treated with TKI for their solid tumors. Third, this study confirmed previously 
reported associations between treatment-emergent macrocytosis and increased PFS in RCC patients.22,28,29 
Fourth, while the study was underpowered to evaluate their effects on survival, cabozantinib and sunitinib 
were also significantly associated with treatment-emergent macrocytosis. Results of this study are 
significant because they support the potential use of macrocytosis as an early predictive biomarker of 
response in solid tumor patients treated with TKIs. 
Among all study patients, the mean time until development of treatment-emergent macrocytosis was 
118 days (or approximately 3.9 months), and was similar among RCC patients, as well as patients treated 
with cabozantinib, pazopanib, or sunitinib where the mean time until treatment-emergent macrocytosis was 
125 days (or 4.2 months), 115 days (or 3.8 months), 129 days (or 4.3 months), and 102 days (or 3.4 months), 
respectively. These results confirm a similar lag until the development of sunitinib-induced macrocytosis 
in previous studies, and demonstrate that time is clearly required before TKIs impact the overall erythrocyte 
volume.22,24,28,29 In our overall study population, median PFS was 393 days, and was 382 and 334 days in 
our RCC and pazopanib-treated patients, respectively. But more importantly, the lower limit of the IQR for 
PFS was still over one month longer than the mean time to treatment-emergent macrocytosis in the overall 
study population (155 versus 118 days), RCC patients (163 versus 125 days), and pazopanib-treated patients 
(163 versus 129 days). However, unlike previously reported results,28 our study was not able to detect a 
significant association between time to treatment-emergent macrocytosis and prolonged PFS in our overall 
study cohort, nor in RCC patients or patients treated with pazopanib. But, despite our inability to detect a 
positive association between time to treatment-emergent macrocytosis and prolonged PFS, results from this 
study do support the idea that it could be a viable predictive pharmacodynamic biomarker. Aside from the 
fact that macrocytosis is an easily obtained and interpretable laboratory test result, it occurred in a majority 
of our patients prior to progression. In addition, while these data support the hypothesis that treatment-
emergent macrocytosis could be used as a predictive biomarker in all solid tumor patients, this hypothesis 
should be tempered due to the fact that many of these solid tumors have quite distinct underlying biologies 
that manifest with different natural histories. Therefore, it is most appropriate to evaluate treatment-
emergent macrocytosis in RCC patients and patients treated with pazopanib. 
For over a decade, investigators have described associations between sunitinib and treatment-emergent 
macrocytosis in RCC patients.23–27,32 In this study, mean ΔMCV for pazopanib and sunitinib (4.5 fL and 
5.6 fL, respectively) were consistent with previously published studies.24,29 Previous studies have also 
concluded that sunitinib-induced macrocytosis was associated with prolonged PFS22,28 and OS.29 Unlike 
these previous studies, significant associations between treatment-emergent macrocytosis and prolonged 
PFS or OS among sunitinib-treated patients in this study were not detected. This may be a reflection of the 
small sample size of patients in the study that were treated with sunitinib (n=27), which underpowered its 
ability to detect an association. However, RCC patients who experienced pazopanib-induced macrocytosis 
achieved a median PFS of nearly 25 months (compared to median 10.5 months among patients with 
normocytosis), which is consistent with RCC patients who experienced sunitinib-induced macrocytosis and 
achieved a median PFS of 21 months (compared to median 5 months among patients with normocytosis).28   
The molecular mechanisms underlying the association between TKI-induced macrocytosis and survival 
are still poorly characterized. However, TKI-induced inhibition of c-KIT and downstream signaling 
transduction pathways of erythroid progenitor development in the bone marrow has been postulated as the 
underlying etiology of treatment-emergent macrocytosis. c-KIT is expressed on the surface of 
hematopoietic progenitor cells where it regulates survival, proliferation and differentiation of red blood 
cells. It is thought that c-KIT plays a significant role in sustaining human stem cell development, influencing 
the proliferation of both human colony-forming cells with high proliferative potential and long-term bone 
marrow cultures.29,33 One proposed mechanism posits that TKI-induced macrocytosis could be due to 
disruption in cell maturation, leading to the release of larger immature erythrocytes into the blood 
stream.23,29 Moreover, one previous study found that bone marrow was hypocellular among sunitinib-
treated patients who developed macrocytosis, which supports the hypothesis that TKI-induced inhibition of 
hematopoietic progenitor cells could be c-KIT-mediated.24 Like previously published data suggests,28 
cabozantinib, pazopanib, and sunitinib did not consistently affect hemoglobin levels or cause 
reticulocytosis, despite the emergence of macrocytosis (Table 2 and Figure 2). TKIs evaluated in this study 
were selected based on their putative potency against c-KIT, where the reported IC50 for each of the six 
TKIs was in the submicromolar range (1.6 nM–100 nM).34–39 Moreover, each of the TKIs that were 
significantly associated with macrocytosis (cabozantinib, pazopanib, and sunitinib) inhibit c-KIT in vivo. 
However, despite evidence of potency against c-KIT in vitro, sorafenib does not inhibit c-KIT in vivo.36 
Only 1.5% of sorafenib-treated patients experienced treatment-emergent macrocytosis in this study, which 
was consistent with previous studies that evaluated macrocytosis and survival among sorafenib-treated 
patients with a solid tumor.24,28 Ultimately, this study was not designed to determine the mechanisms 
underlying the association between macrocytosis and survival, thus, further studies are required to more 
clearly describe this relationship.  
While these data both complement previous work that identified an association between sunitinib-
induced macrocytosis and PFS, and provide compelling rationale to support future prospective lines of 
clinical and translational research inquiry, several limitations were present in this study. First, a modest 
sample size of sunitinib-treated (n=27) and cabozantinib-treated patients (n=18) also precluded detection 
of a significant association between treatment-emergent macrocytosis and PFS. Second, while none of the 
study patients were known to have uncontrolled hypothyroidism, alcoholism, or vitamin B12 or folic acid 
deficiency, laboratory values were inconsistently ordered and social history documentation about alcohol 
consumption were similarly inconsistent across patients during the first 12 months of TKI treatment. In 
particular, thyroid function test results could have added potentially valuable insights because the 
association between sunitinib and thyroid dysfunction has been well-described over the past decade,40–44 
and at least one previous study has shown that both macrocytosis and hypothyroidism were both significant 
predictors of prolonged PFS in sunitinib-treated RCC patients.28 As well, IMDC or MSKCC prognostic 
criteria45,46 could not be evaluated as potential covariates because of inconsistent documentation among 
RCC patients. Last, due to the retrospective study design, data collection was limited to patient standard-
of-care visits.  
In the future, there is a need to prospectively validate these data in large, independent cohort of RCC 
patients, specifically those treated with cabozantinib, pazopanib and sunitinib. Ideally, a future prospective 
study will collect prognostic data to include IMDC and/or MSKCC risk criteria in multivariable evaluations 
of macrocytosis as a predictive pharmacodynamic biomarker among RCC patients.45,46 Additionally, pre-
specified time points for macrocytosis evaluation will be determined a priori, and additional clinical labs 
will be collected to evaluate the association between hypothyroidism treatment-emergent macrocytosis.  
 
Conclusions 
This study confirmed that treatment-emergent macrocytosis could be a predictive pharmacodynamic 
biomarker of prolonged PFS, and possibly prolonged OS, in patients with solid tumor diagnoses who were 
treated with orally administered TKIs. In particular, this study validated the findings from other studies that 
showed a survival advantage for RCC patients who develop treatment-emergent macrocytosis, but 
importantly this is the first study to have revealed a significant association between pazopanib-induced 
macrocytosis and prolonged PFS. These study results are certainly exciting due to the paucity of 
pharmacodynamic biomarkers currently used in routine clinical practice, and these data provide rationale 
to support future lines of prospective inquiry to validate these associations clinically, as well as to determine 
the molecular mechanisms that underlie these associations.  
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